IC
PBYI icon

Ikarian Capital’s Puma Biotechnology PBYI Stock Holding History

Ikarian Capital’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-100,000
Closed -$1.03M – 323
2020
Q4 		$1.03M Buy
+100,000
New +$1.01M 0.05% 177
2020
Q1 		– Sell
-132,700
Closed -$1.16M – 170
2019
Q4 		$1.16M Buy
+132,700
New +$1.1M 0.19% 77

Other funds holding PBYI

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Ikarian Capital's PBYI Position: Q2 2022 in Review

Ikarian Capital sold out of Puma Biotechnology (PBYI) in Q2 2022, closing a stake of 49,843 shares — an estimated $144K sold.

Ikarian Capital first reported a position in PBYI in Q4 2019 and held it in 10 quarters. The position peaked at $2.72M in Q4 2019. 88 funds tracked by Wall St. Rank hold PBYI as of Q2 2022.

  • Ikarian Capital reported no remaining Puma Biotechnology position as of Q2 2022 after selling out during the quarter.
  • Ikarian Capital sold 49,843 Puma Biotechnology shares in Q2 2022, an estimated $144K.
  • Ikarian Capital first reported a position in Puma Biotechnology in Q4 2019 and held it in 10 quarters.
  • Ikarian Capital's Puma Biotechnology position peaked at $2.72M in Q4 2019.
  • 88 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.